Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Kaposi, HIV Infections, Carcinoma, Medullary, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT07137416 2026-05-28

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

Phase 1 Recruiting

36 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT06247995 2026-05-27

NeoB-Cap1

Phase 1/2 Recruiting

58 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT07252726 2026-05-27

Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers

Phase 4 Recruiting

50 enrolled

BreastGenitourinary

Breast Neoplasms, Neoplasm Metastasis, Prostatic Neoplasms

NCT06533059 2026-05-26

A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors

Phase 1 Active not recruiting

110 enrolled

BreastGenitourinaryGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Genital Neoplasms, Female, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04784715 2026-05-22

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

Phase 3 Active not recruiting

1,157 enrolled 1 FDA

Breast

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis

NCT05277051 2026-05-22

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

Phase 1 Active not recruiting

152 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT06238479 2026-05-22

EXCEED

Phase 1 Active not recruiting

490 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Ureteral Neoplasms, Urologic Neoplasms, Triple Negative Breast Neoplasms

NCT06465069 2026-05-22

NEXUS-01

Phase 1 Recruiting

420 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Ureteral Neoplasms, Urologic Neoplasms, Triple Negative Breast Neoplasms

NCT04588246 2026-05-20

Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery

Phase 3 Terminated

19 enrolled 19 charts

BreastCNSDermatologicGastrointestinalGenitourinaryThoracic

Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Small Cell Lung Carcinoma

NCT07029399 2026-05-19

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

Phase 1 Recruiting

361 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT06757634 2026-05-18

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

Phase 3 Recruiting

1,180 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

Phase 1 Terminated

154 enrolled

BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

NCT05374512 2026-05-15

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

Phase 3 Active not recruiting

644 enrolled 1 FDA

Breast

Breast Neoplasms, Neoplasm Metastasis

Clinical Trials

ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer

ASPEN-09-03

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

OMNIRAY

HERMIA

A Study of LY4175408 in Participants With Advanced Cancer

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

NeoB-Cap1

Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers

A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

EXCEED

NEXUS-01

Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)